NCT00425321 / 2006-003983-73: Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy |
|
|
| Completed | 2a | 259 | US, Europe, RoW | RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Rheumatoid Arthritis | 01/08 | 01/08 | | |
